Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

C4042

Sigma-Aldrich

Captopril

≥98% (HPLC), powder, angiotensin converting enzyme inhibitor

Synonyme(s) :

N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C9H15NO3S
Numéro CAS:
62571-86-2
Poids moléculaire :
217.29
Numéro Beilstein :
477887
Numéro CE :
263-607-1
Numéro MDL:
MFCD00168073
Code UNSPSC :
12352200
ID de substance PubChem :
57654003
Nomenclature NACRES :
NA.77

product name

Captopril, ≥98% (HPLC), powder

Source biologique

synthetic

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Couleur

white to off-white

Pf

104-108 °C (lit.)

Solubilité

water: 100 mg/mL, clear to very slightly hazy, colorless to faintly yellow

Auteur

Bristol-Myers Squibb

Température de stockage

room temp

Chaîne SMILES 

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

Clé InChI

FAKRSMQSSFJEIM-RQJHMYQMSA-N

Informations sur le gène

human ... ACE(1636) , AGTR1(185) , AGTR2(186) , ECE1(1889)
rat ... Ace(24310)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Captopril has been used:
  • to examine the influence of timing of captopril treatment on efficacy in transverse aortic constriction (TAC) mice
  • as an angiotensin-converting enzyme inhibitor and orally administered to unrestrained Wistar Kyoto rats in an approach to study its effects of angiogenesis inhibition and interdependency with other drugs
  • used as a positive control in spectrophotometric assay to study the angiotensin-converting enzyme inhibitory activity

Actions biochimiques/physiologiques

Captopril is known to decrease the cardiovascular complications arising due to myocardial infarction. It is an effective drug in treating diabetic nephropathy and renal disease. Captopril acts by reducing cardiac related inflammation, fibrosis and calcification.
Angiotensin converting enzyme inhibitor. Inhibits the formation of angiotensin II, a bioactive peptide that stimulates angiogenesis and increases microvessel density.

Caractéristiques et avantages

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Neuropeptidases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H341,H360F

Classification des risques

Muta. 2 - Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

The primary benefits of angiotensin-converting enzyme inhibition on cardiac remodeling occur during sleep time in murine pressure overload hypertrophy
Martino TA, et al.
Journal of the American College of Cardiology, 57(20), 2020-2028 (2011)
Tami A Martino et al.
Journal of the American College of Cardiology, 57(20), 2020-2028 (2011-05-14)
Our objective was to test the hypothesis that there is a significant diurnal variation for the therapeutic benefit of angiotensin-converting enzyme (ACE) inhibitors on pressure-overload cardiovascular hypertrophy. Physiological and molecular processes exhibit diurnal rhythms that may affect efficacy of disease
Identification of antihypertensive peptides derived from low molecular weight casein hydrolysates generated during fermentation by Bifidobacterium longum KACC 91563
Ha GE, et al.
Korean journal for food science of animal resources, 35(6), 738-738 (2015)
Current Cardiovascular Drugs, 28-28 (2005)
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
Pfeffer MA, et al.
The New England Journal of Medicine, 349(20), 1893-1906 (2003)
Afficher tous les articles scientifiques apparentés

Articles

Critical Inhibitor Characteristics to Consider

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.

Critical Inhibitor Characteristics to Consider

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.

Critical Inhibitor Characteristics to Consider

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.

Critical Inhibitor Characteristics to Consider

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.

Afficher tout

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique